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In 1998, a varicella-zoster virus glycoprotein E (gE) mutant virus
(VZV-MSP) was isolated from a child with chickenpox. VZV-
MSP, representing a second VZV serotype, was considered a
rarity. We isolated another VZV-MSP-like virus from an elderly
man with herpes zoster. These gE mutant viruses may have
arisen through independent mutation or may represent a distinct
VZV subpopulation that emerged more than 50 years ago.
n 1998, a VZV mutant virus (VZV-MSP) was discovered in
Minneapolis-St. Paul, Minnesota; the virus had a missense
mutation in the preponderant surface glycoprotein called gE
(1,2). The mutation in VZV-MSP led to a lost B-cell epitope in
the gE ectodomain. We define “mutant” as a virus with distinc-
tive phenotypic characteristics associated with a nucleotide
polymorphism and “variant” as a more inclusive term to
include any virus with nucleotide polymorphisms whether or
not the virus has a distinguishable associated phenotype. Many
methods for differentiating VZV variants and their application
to molecular epidemiologic studies have been described (3–8).
However, no nucleotide polymorphisms, with the exception of
the gE mutation in VZV-MSP, have conclusively been linked
to distinguishable phenotypes.
Before 1995, a general assumption was that only one VZV
serotype was found around the world (5,9). Similarly, the pub-
lished sequence of the Dumas laboratory strain was generally
accepted as the standard for all strains (10,11). Whether the
VZV-MSP mutant virus exhibits increased fitness is not yet
known. However, the mutant virus has a recognizable pheno-
type consisting of accelerated cell spread in both cell culture
and the SCID-hu mouse (severe combined immunodeficient
mouse with a human skin implant) model of VZV pathogene-
sis as well as a strikingly different pattern of egress, as docu-
mented by scanning electron microscopy (2). VZV-MSP was
isolated from a child with leukemia who contracted chicken-
pox and was admitted to hospital for treatment with intrave-
nous acyclovir. The discovery of a VZV gE variant virus was
unexpected; one hypothesis is that the mutation occurred for
the first time in the virus replicating in the index case and that
the discovery was a serendipitous event unlikely to ever occur
again.
We describe the second case of a gE mutant virus found in
North America. This discovery provides evidence that the gE
mutant virus was unlikely to have occurred as a serendipitous
chance mutation.
Case Report
In December 1999, a 75-year-old man from Vancouver,
British Columbia, Canada, arrived at the hospital with severe
zoster lesions on his face (in division V1 of the left trigeminal
cranial nerve). Painful postherpetic neuralgia with headaches,
associated with occasional blurring of vision and lasting for 6
months, developed. The patient was treated with famciclovir
(500 mg three times a day for 7 days). A swab of the facial
vesicles was obtained from the patient during acute zoster
before famciclovir treatment. 
Characteristic VZV cytopathogenic effect was seen after 9
days in cell culture. Results of immunofluorescence staining,
performed with a commercial kit (Meridian Diagnostics, Cin-
cinnati, OH) by using the anti-gE monoclonal antibody (MAb
3B3), were negative. Staining with monoclonal antibody con-
jugates for cytomegalovirus and human herpes simplex viruses
was also negative. Electron microscopy indicated the presence
of enveloped virus characteristic of herpesviruses.
Polymerase chain reaction amplification and subsequent
DNA sequencing confirmed the virus genome to be VZV
(hereafter referred to as VZV-BC). The VZV-BC strain was
then analyzed in ORF68 (encodes gE and contains the 3B3
MAb epitope) and found to have an identical nucleotide
sequence to VZV-MSP (GenBank accession no. AY005330).
The VZV-BC and VZV-MSP strains differed from the proto-
type Dumas VZV strain (GenBank accession no. X04370) in
ORF68 by a single G448A nucleotide mutation (D150N amino
acid substitution) in the 3B3 epitope of gE (Table). VZV-MSP
and VZV-BC were also identical in nucleotide sequence in
ORF62 (IE62) and ORF37 (gH). In short, VZV-BC was
closely related genetically, if not identical, to the VZV-MSP
mutant virus.
Conclusions
VZV-MSP was the first community-acquired VZV strain
shown to have a phenotype distinguishable from the traditional
VZV phenotype. This case report documents the existence of a
second isolate with the same gE genotype. VZV-MSP has been
shown to have attributes consistent with increased virulence in
the SCID-hu mouse model (2). Both VZV-MSP and VZV-BC
are escape mutants (i.e., they have lost a B-cell epitope present
in the prototypic Dumas virus from Holland, as well as other
viruses from North America, Europe, and Asia, including the
Oka varicella vaccine strain from Japan) (11). We have previ-
ously shown that the same gE epitope is involved in both com-
plement-dependent neutralization (12) as well as antibody-
dependent cellular cytotoxicity (13). Considering the cell cul-
ture and animal model data for VZV-MSP and the lost B-cell
epitope resulting from the D150N gE mutation, this mutation
should be monitored to determine whether it plays a role in
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more severe cases of varicella or zoster or in breakthrough
varicella in previously immunized children. 
The origin of this variant may be the same gE mutation,
occurring separately in two patients by chance. The argument
favoring chance was raised after the discovery of the first gE
mutant; however, we find this argument less compelling after
the discovery of a second VZV strain with an identically
mutated gE antigenic site, just 4 years later. Two other possi-
bilities for its origin seem more plausible. The same gE muta-
tion may have occurred from selective antibody pressure. In an
article from the laboratory of the Nobel laureate Zinkernagel
(14), the investigators showed that antibody escape variant
viruses were more likely to arise in animals with deficient cel-
lular immunity. The original VZV-MSP isolate was obtained
from chickenpox in a child under treatment for leukemia, a
condition known to be associated with depressed immunity.
The second isolate was obtained from an elderly adult with
herpes zoster, a condition that may be related to diminished
immunity from aging. One of the antibody-escape glycopro-
tein mutant viruses described by the Zinkernagel laboratory
had the identical aspartic acid to asparagine mutation seen in
the two VZV-MSP glycoprotein variant viruses. However,
mutant viruses probably would have been discovered in the
immunocompromised population. The most likely scenario is
that VZV-MSP is a previously unrecognized subpopulation of
VZV that has been circulating for more than 50 years in cir-
cumscribed regions of northern United States and Canada. The
timeline is based on the decade when the British Columbia
patient likely first contracted chickenpox as a child. The gE
sequencing analyses of 30 isolates by Shankar et al. (15) did
not uncover a D150N gE mutation; therefore, larger studies
need to be conducted to determine the prevalence of this
mutant virus in North America.
We conclude that diagnosticians should be aware of the
existence of VZV-MSP-like strains and the potential for false-
negative testing results with single MAb-based antigen-detec-
tion kits for VZV or other herpesviruses. Further clinical
observations are needed to fully assess the biological signifi-
cance of the VZV gE mutant virus.
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Table. Amino acid sequences of VZV strains Dumas, MSP and BC in the 3B3 monoclonal antibody epitopea
Codon
150 151 152 153 154 155 156 157 158 159 160 161
D u m a s D Q R QYGDVFKGD
V Z V - M S P N Q R QYGDVFKGD
V Z V - B C N Q R QYGDVFKGD
aVZV-BC, varicella-zoster virus found in British Columbia; VZV-MSP, varicella-zoster virus glycoprotein E mutant virus.